X4 Pharmaceuticals, Inc.XFORNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+225.0%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+225.0%/yr
vs -51.3%/yr prior
Acceleration
+276.3pp
Accelerating
Percentile
P95
Near historical high
vs 3Y Ago
34.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 33.41% |
| Q3 2025 | 6.95% |
| Q2 2025 | -94.57% |
| Q1 2025 | 53.48% |
| Q4 2024 | 3.19% |
| Q3 2024 | -12.21% |
| Q2 2024 | 9.64% |
| Q1 2024 | -21.14% |
| Q4 2023 | -33.34% |
| Q3 2023 | 2.79% |
| Q2 2023 | 19.18% |
| Q1 2023 | -38.66% |
| Q4 2022 | 0.97% |
| Q3 2022 | -4.34% |
| Q2 2022 | 8.59% |
| Q1 2022 | -6.22% |
| Q4 2021 | -33.98% |
| Q3 2021 | 26.20% |
| Q2 2021 | -1.81% |
| Q1 2021 | -6.37% |
| Q4 2020 | -20.12% |
| Q3 2020 | -29.26% |
| Q2 2020 | 28.69% |
| Q1 2020 | -72.48% |
| Q4 2019 | 27.46% |
| Q3 2019 | 10.07% |
| Q2 2019 | -21.63% |
| Q1 2019 | -65.19% |
| Q4 2018 | 12.91% |
| Q3 2018 | 39.54% |
| Q2 2018 | -10.92% |
| Q1 2018 | 5.53% |
| Q4 2017 | -152.35% |
| Q3 2017 | 20.03% |
| Q2 2017 | -81.04% |
| Q1 2017 | -11.54% |
| Q4 2016 | 0.00% |
| Q1 2016 | 0.00% |